| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| ln Vitro |
Compared with Blebbistatin, MT-228 (10-3-100 μM) showed greater cardiac safety and selectivity in ATPase assays, with a KINMIIB value of 1.5 μM[1]. MT-228 showed excellent concordance with cell division (EC50 = 1.0 μM)[1].
|
|---|---|
| ln Vivo |
MT 228 (5–10 mg/kg, intraperitoneal injection, single dose) was well tolerated in mice at doses of at least 10 mg/kg [1]. MT-228 (0.5–5 mg/kg, intraperitoneal or intravenous injection, single dose) disrupted stimulant cravings in mice and rats [1].
|
| Animal Protocol |
Animal/Disease Models:8-10 week old male C57BL/6 mice (25-30 g) [1]
Doses: Single intraperitoneal injection Route of Administration: 5, 7.5, 10 mg/kg Experimental Results: No significant changes were observed in the distance the mice moved during the first 10 minutes or the entire 40-minute test period after injection. The movement speed of the mice did not change, and there was no difference in the time spent in the central and peripheral areas of the open field. Animal/Disease Models:8-10 week old male C57BL/6 mice (25-30 g) [1] Doses: Single intraperitoneal injection Route of Administration: 0.5, 1, 2.5, 5 mg/kg Experimental Results: Doses as low as 0.5 mg/kg disrupted the craving for methamphetamine (METH) in mice. No effect was placed on the strong preference of mice for rooms containing cocaine (COC) (5 mg/kg). No effect was placed on any parameters of the elevated cruciate maze, including the total distance traveled in the maze, the latency to enter an open (unprotected) arm, or the time spent in an open arm (5 mg/kg). Animal/Disease Models:Adult male rats, weighing 250-300 g [1] Doses: Single intravenous injection 30 minutes before the test Route of Administration: 1 mg/kg Experimental Results: Reduced lever-pressing behavior in rats. Eliminated methamphetamine (METH) cravings in rats for at least one month. |
| References |
| Molecular Formula |
C19H19N3O3
|
|---|---|
| Molecular Weight |
337.37
|
| CAS # |
2404652-24-8
|
| Appearance |
Light yellow to yellow solid
|
| SMILES |
O=C1[C@@]2(O)C(N(C3=CC(OC)=NC=C3)CC2)=NC4=C1C=C(C)C(C)=C4
|
| Synonyms |
BPN-0026709
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~24.69 mM; ultrasonic and warming and heat to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (8.3 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (8.3 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9641 mL | 14.8205 mL | 29.6410 mL | |
| 5 mM | 0.5928 mL | 2.9641 mL | 5.9282 mL | |
| 10 mM | 0.2964 mL | 1.4821 mL | 2.9641 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
